Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 2,409 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Procedure Clear all

Conditions: Bladder Cancer
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 4
States / cities: Los Angeles, California • San Francisco, California • Dallas, Texas

Conditions: Bladder Cancer, Bladder Tumor, Muscle-Invasive Bladder Cancer
Interventions: Nivolumab, Radical cystectomy (RC), Bempegaldesleukin; Biological · Procedure
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 15
States / cities: Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 12 more

Conditions: Bladder Cancer
Interventions: Gemcitabine, Carboplatin, Panitumumab, radical cystectomy; Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Stroke, Aphasia, Aphasia Following Cerebral Infarction
Interventions: Transcranial Magnetic Stimulation (TMS), Modified Constraint Induced Language Therapy (mCILT); Device · Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 85 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Rehabilitation Post-amputation
Interventions: Near-Infrared Spectroscopy (NIRS) Sensor; Device
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cerebral Stroke
Interventions: Configuration task; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COVID-19
Interventions: Tocilizumab, Standard of Care; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer
Interventions: MRI-guided Transurethral Ultrasound Ablation; Device
Lead sponsor: Profound Medical Inc.; Other
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 8
States / cities: Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 5 more

Conditions: Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
Interventions: Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside; Drug · Other
Lead sponsor: CG Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 90
States / cities: Homewood, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 72 more

Conditions: Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
Interventions: B-701, Pembrolizumab; Drug
Lead sponsor: Rainier Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 8
States / cities: Greenbrae, California • Fort Wayne, Indiana • Louisville, Kentucky + 5 more

Conditions: Traumatic Brain Injury (TBI), Intracerebral Hemorrhage
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer, HER2-negative Breast Cancer, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Deleterious PALB2 Gene Mutation
Interventions: Niraparib, Dostarlimab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 8
States / cities: New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Occult Bleeding, Hemorrhage, Hemorrhagic Shock
Interventions: Not listed
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Candidemia
Interventions: Anidulafungin, Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 24
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 7 more

Conditions: Infiltration, Extravasation, IV Infiltration, IV Extravasation, Extravasation of Diagnostic and Therapeutic Materials
Interventions: Not listed
Lead sponsor: ivWatch, LLC; Industry
Eligibility: Up to 12 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Body Fat
Interventions: Cutera truSculpt; Device
Lead sponsor: Cutera Inc.; Industry
Eligibility: 24 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Dental Caries
Interventions: Not listed
Lead sponsor: Dental Practice-Based Research Network; Network
Eligibility: 19 Years and older
Enrollment: 334 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Birmingham, Alabama • Gainesville, Florida • Minneapolis, Minnesota + 1 more

Conditions: Cervical Spinal Cord Plasticity
Interventions: SCAP, MagPro X100, Digitimer DS8R, Paired non-associative stimulation; Other · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Great Saphenous Vein Insufficiency
Interventions: Sonovein Treatment; Device
Lead sponsor: Englewood Hospital and Medical Center; Other
Eligibility: 22 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Englewood, New Jersey

Conditions: Spinal Cord Injury, Orthostatic Hypertension, Autonomic Dysreflexia
Interventions: Spinal Cord Transcutaneous Stimulation; Device
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Louisville, Kentucky

Conditions: Bladder Cancer
Interventions: SCH 721015; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Carcinoma, Squamous Cell, Carcinoma, Squamous, Squamous Cell Carcinoma, Lung Neoplasms, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms
Interventions: DNA Extraction; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HER2-normal
Interventions: eribulin mesylate; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Lebanon, New Hampshire • New York, New York

Conditions: Genetic Polymorphism
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Predicting BCG Response

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Transcranial Magnetic Stimulation + Language Therapy to Treat Subacute Aphasia

Assessing the Feasibility of a Novel Non-Invasive Sensor for Guiding Wounded Warrior Rehabilitation

Can we Train Patients With Chronic Stroke Out of Abnormal Hand Synergy?

Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19

Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

Hemodynamic ABI Monitor

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

A 48 Subject Study Using Non-invasive Multi-Technology Measurements for Early Detection of Ongoing Hemorrhage

Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis

Monitoring the Peripheral Intravenous Infusion Site for Infiltration and Extravasation

Performance Evaluation of the truSculpt Radiofrequency Device for Lipolysis of Abdominal Fat

DPBRN Development of a Patient Based Provider Intervention for Early Caries Management

Cervical Spinal Cord Associative Plasticity

Minimally Invasive Treatment of Primary Great Saphenous Vein (GSV) Insufficiency Using High Intensity Focused Ultrasound (HIFU)

Non-invasive Spinal Cord Stimulation and Blood Pressure Regulation After Spinal Cord Injury

1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer

Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma

Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications